1α, 25-Dihydroxyvitamin D regulates hypoxia-inducible factor-1α in untransformed and Harvey-ras transfected breast epithelial cells.

Cancer Letters
Yan JiangDorothy Teegarden

Abstract

The purpose of this study was to determine the mechanism by which 1α, 25-dihydroxyvitamin D (1,25(OH)(2)D) alters hypoxia-inducible factor-1α (HIF-1α) protein in untransformed and Harvey-ras (H-ras) oncogene transfected MCF10A breast epithelial cells. Treatment with 1,25(OH)(2)D (10nM) increased both mRNA (2.55±0.6-fold vs. vehicle, p=0.03) and protein levels (2.37±0.3-fold vs. vehicle, p<0.0001) of HIF-1α in MCF10A cells in 12h, which remained elevated at 24h. However, in H-ras transfected MCF10A cells, 1,25(OH)(2)D treatment increased HIF-1α protein level (2.08±0.38-fold vs. vehicle, p=0.05) at 12h, with no change in mRNA level and HIF-1α protein level returned to baseline after 24h. A transcription inhibitor prevented the 1,25(OH)(2)D induction of HIF-1α protein and mRNA levels in MCF10A cells, but failed to alter the induction of HIF-1α protein level in H-ras transfected MCF10A cells. On the other hand, inhibition of proteasomal degradation prevented the 1,25(OH)(2)D-induced HIF-1α protein level in H-ras transfected MCF10A but not in MCF10A cells. These results support that 1,25(OH)(2)D regulates HIF-1α protein level via transcriptional regulation in MCF10A cells in contrast to through proteosomal degradation with the prese...Continue Reading

References

Feb 1, 1997·Kidney International·G L SemenzaA Yu
Apr 1, 1998·Journal of the National Cancer Institute·R A HiattN Orentreich
Oct 8, 1999·Public Health Nutrition·E C JanowskyB S Hulka
Aug 6, 2000·Circulation Research·D J MantellA E Canfield
Feb 24, 2001·Cancer Metastasis Reviews·G L Semenza
Sep 11, 2001·Biochemical and Biophysical Research Communications·A SodhiJ S Gutkind
Oct 13, 2001·Breast Cancer Research : BCR·C W PughP H Maxwell
Oct 16, 2002·Journal of Korean Medical Science·Yang-Sook ChunJong-Wan Park
Mar 20, 2003·Molecular and Cellular Endocrinology·Glendon M ZinserJoEllen Welsh
Mar 20, 2004·Experimental & Molecular Medicine·Ji-Won LeeKyu-Won Kim
Jul 1, 2004·The Journal of Steroid Biochemistry and Molecular Biology·Glendon M Zinser, JoEllen Welsh
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexandra GiatromanolakiEfthimios Sivridis
Dec 29, 2005·American Journal of Public Health·Cedric F GarlandMichael F Holick
Mar 21, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Cedric F GarlandFrank C Garland
Apr 27, 2007·Cancer Metastasis Reviews·Denise A Chan, Amato J Giaccia
Nov 22, 2007·Breast Cancer Research and Treatment·Petra van der GroepPaul J van Diest
Apr 9, 2008·The Biochemical Journal·Patrick van UdenSonia Rocha
Oct 3, 2008·The Journal of Nutritional Biochemistry·Laura M TaberDorothy Teegarden
Jun 16, 2009·Annals of Epidemiology·Cedric F GarlandFrank C Garland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.